Phathom Pharmaceuticals (PHAT) Stock Highlights

7.45 | -4.73%

2024-12-21 04:14:24

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Statistics

Range Today

7.39 7.83

Volume Today 2.48M

Range 1 Year

6.07 19.71

Volume 1 Year 226.78M

Range 3 Year

5.84 20.3

Volume 3 Year 382.72M

Range 10 Year

5.84 64.54

Volume 10 Year 440.34M

Highlights

Market Capitalization 1.26B (small)

Floating Shares 48.58M

Current Price 7.45

Price To Earnings -3.62

Price To Revenue 131.36

Earnings Per Share -5.23

Payout Ratio 0%

Performance

Latest -4.73%

1 Month -20.58%

3 Months -60.12%

6 Months -36.54%

1 Year -15.34%

3 Years -60.08%

5 Years -63.23%

10 Years -66.89%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.